COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #124
Source   PDF   Share   Tweet
See all 182 studies
9/9
Positive
Late treatment study
Alamdari et al., Tohoku J. Exp. Med., 2020, 252, 73-84, doi:10.1620/tjem.252.73 (Peer Reviewed)
Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran
Retrospective 459 patients in Iran 93% using HC Q, showing HC Q mortality RR 0.45, p = 0.028. HC Q was the only antiviral that showed a significant difference. Small number of control patients and subject to confounding by indication. Average admission delay 5.72 days.
death, ↓55.0%, p=0.03
Source   PDF   Share   Tweet
See all 182 studies
Please send us corrections, updates, or comments.
Submit